$OURA

Smart Ring Maker Oura Holds Initial Public Offering

Oura, a maker of health-tracking smart rings, is going public on the Nasdaq at a $14.1B valuation. The company is selling 50M shares at $40-$44 each, aiming to raise $2.2B. Oura reported a $924.3M net loss on $1.21B revenue for the nine months ended June 30.

Original reporting
Published Sep 21, 2026, 3:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 3:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Smart Ring Maker Oura Holds Initial Public Offering — source image
Decision brief

The 30-second read

$OURABullishHigh
01

Why it matters

The IPO provides Oura with capital to expand product lines and enter new markets, while offering investors exposure to a fast‑growing health‑monitoring niche.

02

Market read

Oura's debut is a marquee event for the consumer health‑tech sector and could influence pricing dynamics for similar IPOs.

03

What to watch

Potential regulatory scrutiny of health data privacy and competition from larger wearables players.

Relevance 9/10Novelty 9/10Timing: today (Sept 21) IPO launch

Background

Oura, a Finnish‑origin smart‑ring maker, previously raised $875M at an $11B valuation in 2025 and sold 3.6M rings last year.

Company-level read

Ticker impact

$OURABullishHigh confidence
Context

Oura announced its IPO on Nasdaq today, offering 50M shares at $40-$44 to raise up to $2.2B.

Expected impact

Potential upside of 15‑20% on debut if demand holds.

Evidence & confidence

Large valuation, sizable capital raise, and being the biggest tech IPO in the U.S. this year create significant buying interest.

Market effects

Highlights continued investor appetite for consumer health‑tech and wearable devices.

Adds a high‑profile tech listing to the Nasdaq, supporting US market depth.

Sets a benchmark for future health‑tech IPOs worldwide.

Counterpoint

If the IPO is over‑priced, post‑pricing sell‑off could trigger a sharp decline.

Key entities

  • Goldman Sachs

    Lead underwriter for the Oura IPO.

  • Morgan Stanley

    Co‑lead underwriter for the Oura IPO.

Related articles

$COINMedAI 8/10

Coinbase Opens IPO Access — Oura Is First, But There's a Catch

Coinbase launched a new service allowing eligible U.S. retail customers to request allocations in IPOs, starting with Oura's $2.2B IPO. Oura plans to sell 13.5M shares at $40-$44 each, with a fully diluted valuation of about $15.62B. Coinbase's IPO access prioritizes long-term investors, discouraging early selling.

$OURAHighAI 9/10

Smart ring maker Oura targets $2.2 billion in US listing

Oura Inc, a smart ring maker, aims to raise $2.2B in a US IPO, offering 50M shares at $40-$44 each. The company could be valued at $14.1B-$15B. Oura reported a $924.3M net loss on $1.21B revenue for the nine months ended June 30. The IPO is expected to price on September 29, with shares trading on Nasdaq under ticker OURA.

$COINHigh

Coinbase IPO News: US Retail Access Opens, With Oura Up First

Coinbase launched a feature allowing eligible US retail customers to request IPO shares, starting with Oura. Oura plans to offer 13.5M shares priced between $40 and $44, listing on Nasdaq as OURA. Coinbase's stock (COIN) rose 3.5% to $201.05 on the news, with a market cap of $53.04B. Oura's IPO is expected to price this week.

$OURAHighAI 9/10

Oura smart ring IPO roadshow launches, targets $2.2 billion

Oura Health launched its IPO, aiming to raise $2.2B by selling 50M shares at $40-$44 each, targeting a $15.62B valuation. Trading under 'OURA' on Nasdaq, it sold 3.6M rings in the past year with $1.21B revenue. Eli Lilly and Dragoneer may invest $100M and $300M respectively. The company faces a lawsuit over sleep tracking accuracy claims.